WallStSmart

Aveanna Healthcare Holdings Inc (AVAH)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 2225% more annual revenue ($56.58B vs $2.43B). NVS leads profitability with a 23.9% profit margin vs 9.3%. AVAH trades at a lower P/E of 6.2x. AVAH earns a higher WallStSmart Score of 62/100 (C+).

AVAH

Buy

62

out of 100

Grade: C+

Growth: 8.7Profit: 7.5Value: 8.3Quality: 5.0

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVAHUndervalued (+57.0%)

Margin of Safety

+57.0%

Fair Value

$18.54

Current Price

$6.55

$11.99 discount

UndervaluedFair: $18.54Overvalued
NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVAH4 strengths · Avg: 9.5/10
P/E RatioValuation
6.2x10/10

Attractively priced relative to earnings

Return on EquityProfitability
61.6%10/10

Every $100 of equity generates 62 in profit

EPS GrowthGrowth
465.2%10/10

Earnings expanding 465.2% YoY

Revenue GrowthGrowth
27.4%8/10

Revenue surging 27.4% year-over-year

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

AVAH1 concerns · Avg: 3.0/10
Market CapQuality
$1.42B3/10

Smaller company, higher risk/reward

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AVAH

The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 27.4% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : AVAH

The primary concerns for AVAH are Market Cap.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

AVAH profiles as a growth stock while NVS is a declining play — different risk/reward profiles.

AVAH carries more volatility with a beta of 2.09 — expect wider price swings.

AVAH is growing revenue faster at 27.4% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

AVAH scores higher overall (62/100 vs 51/100) and 27.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aveanna Healthcare Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?